SPWM
TEVA icon

Straight Path Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Straight Path Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,000
Closed -$606K – 149
2025
Q3 		$606K Buy
+30,000
New +$527K 0.16% 69

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Straight Path Wealth Management's TEVA Position: Q1 2026 in Review

Straight Path Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 50,000 shares — an estimated $1.56M sold.

Straight Path Wealth Management first reported a position in TEVA in Q4 2021 and held it in 17 quarters. The position peaked at $1.56M in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Straight Path Wealth Management reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Straight Path Wealth Management sold 50,000 Teva Pharmaceuticals shares in Q1 2026, an estimated $1.56M.
  • Straight Path Wealth Management first reported a position in Teva Pharmaceuticals in Q4 2021 and held it in 17 quarters.
  • Straight Path Wealth Management's Teva Pharmaceuticals position peaked at $1.56M in Q4 2025.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Straight Path Wealth Management's 13F filing for Q1 2026, filed 23 Apr 2026.